Published in Neurological Diseases and Disorders Weekly, June 1st, 2000
Aripiprazole was also shown to be better tolerated than haloperidol.
The results of the study were presented during the Annual Meeting of the American Psychiatric Association in May 2000.
"We are very excited about the first Phase III study results with aripiprazole," said Peter S. Ringrose, PhD, Bristol-Myers Squibb Co. (BMY). "Our partner Otsuka has discovered a potentially best-in-class agent for the treatment of schizophrenia, and we hope that this drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Neurological Diseases and Disorders Weekly